Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Deferred Revenue (2021 - 2023)

Historic Current Deferred Revenue for InMed Pharmaceuticals (INM) over the last 3 years, with Q4 2023 value amounting to $28656.0.

  • InMed Pharmaceuticals' Current Deferred Revenue rose 7720.61% to $28656.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $28656.0, marking a year-over-year increase of 7720.61%. This contributed to the annual value of $16171.0 for FY2023, which is N/A changed from last year.
  • InMed Pharmaceuticals' Current Deferred Revenue amounted to $28656.0 in Q4 2023, which was up 7720.61% from $16171.0 recorded in Q2 2023.
  • In the past 5 years, InMed Pharmaceuticals' Current Deferred Revenue ranged from a high of $28656.0 in Q4 2023 and a low of $8390.0 during Q4 2021
  • Its 3-year average for Current Deferred Revenue is $15737.3, with a median of $16171.0 in 2022.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 9274.14% in 2022, then surged by 7720.61% in 2023.
  • InMed Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $8390.0 in 2021, then surged by 92.74% to $16171.0 in 2022, then skyrocketed by 77.21% to $28656.0 in 2023.
  • Its last three reported values are $28656.0 in Q4 2023, $16171.0 for Q2 2023, and $16171.0 during Q1 2023.